(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 September 2010 (16.09.2010)

PCT

(10) International Publication Number
WO 2010/105082 A1

(51) International Patent Classification:
A61K 31/18 (2006.01) *A61P 35/04* (2006.01)
A61K 31/4412 (2006.01)

(21) International Application Number:
PCT/US2010/027021

(22) International Filing Date:
11 March 2010 (11.03.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/159,397 11 March 2009 (11.03.2009) US

(71) Applicant *(for all designated States except US)*: **ARDEA BIOSCIENCES, INC.** [US/US]; 4939 Directors Place, San Diego, CA 92121 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: **CHAPMAN, Mark, S.** [US/US]; 3520 Vista de la Orilla, San Diego, CA 92117 (US).

(74) Agents: **SHIMEI, Barbara** et al.; Bayer Healthcare, LLC, 555 White Plains Road, Tarrytown, NY 10591 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

(54) Title: TREATMENT OF PANCREATIC CANCER

FIGURE 1

Tumor growth curves showing the group median tumor volumes as a function of time (days)



(57) Abstract: The present invention relates to the field of oncology and relates to use of (*S*)-N- (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1 -(2,3-dihydroxypropyl)cyclopropane-1 -sulfonamide or a pharmaceutically acceptable salt thereof or N-(4-(2-fluoro-4-iodophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridin- 3-yl)cyclopropanesulfonamide or a polymorph thereof, or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions comprising the same, for the preparation of a medicament for the treatment of pancreatic cancer. Further, the present invention provides methods for administering a compound disclosed herein to an individual in need thereof by administering (*S*)-N-(3,4-difluoro-2-(2-fluoro-4- iodophenylamino)-6-methoxyphenyl)-1 -(2,3-dihydroxypropyl)cyclopropane-1 - sulfonamide or a pharmaceutically acceptable salt thereof or N-(4-(2-fluoro-4- iodophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridin-3- yl)cyclopropanesulfonamide, or a polymoph thereof, or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions comprising the same.

WO 2010/105082 A1